Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 11, Pages 2716-2727
Publisher
Springer Nature
Online
2014-05-07
DOI
10.1038/bjc.2014.230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNAs targeting EGFR signalling pathway in colorectal cancer
- (2013) Jitka Mlcochova et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- LGR5-Positive Colon Cancer Stem Cells Interconvert with Drug-Resistant LGR5-Negative cells and are Capable of Tumor Reconstitution
- (2012) Shinta Kobayashi et al. STEM CELLS
- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- (2011) C. Mao et al. ANNALS OF ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells
- (2010) L Xu et al. ONCOGENE
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor
- (2009) Kirstine Roepstorff et al. TRAFFIC
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
- The biological role of HGF-MET axis in tumor growth and development of metastasis
- (2007) Ewa Lesko Frontiers in Bioscience-Landmark
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now